PRAME and cutaneous melanoma: T cell engagers targeting PRAME are presently undergoing extensive evaluation in large phase 1 and 2 clinical trials for all recurrent or refractory PRAME-positive solid tumors, encompassing cutaneous melanoma (NCT05958121 and NCT04262466).